Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Gastroenterol Hepatol ; 17(12): 2610-2612, 2019 11.
Article in English | MEDLINE | ID: mdl-30851477

ABSTRACT

Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.


Subject(s)
Crohn Disease/drug therapy , Remission Induction , Ustekinumab/blood , Ustekinumab/therapeutic use , Biomarkers/analysis , C-Reactive Protein/analysis , Feces/chemistry , Gastrointestinal Agents/blood , Gastrointestinal Agents/therapeutic use , Humans , Leukocyte L1 Antigen Complex/analysis , Predictive Value of Tests , Prospective Studies , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...